Although it is established that growth factors and prostaglandins function in the maintenance of gastric mucosal integrity and in the healing of gastric mucosal injury and ulceration, the regulatory relationship between growth factors and prostaglandins in the gastric mucosa is not well characterized. Therefore, we investigated whether hepatocyte growth factor (HGF) affects expression of COX-2 (the inducible form of the prostaglandin synthesizing enzyme, cyclooxygenase) in gastric epithelial cells and whether this action is mediated through the MAP (ERK) kinase signaling pathway. In RGM1 cells (an epithelial cell line derived from normal rat gastric mucosa), HGF caused an increase in COX-2 mRNA and protein by 236% and 175%, respectively (both P<0.05). This induction of COX-2 expression was abolished by pretreatment with the MAPK kinase (MEK) inhibitor PD98059. HGF also triggered a 13-fold increase in c-Met/HGF receptor phosphorylation (P<0.005) and increased ERK2 activity by 684% (P<0.01). Pretreatment with PD98059 abolished the HGF-induced increase in ERK2 activity, but not c-Met/HGF receptor phosphorylation. The specific inhibitor of p38 MAP kinase, SB203580, had no effect on HGF-induced COX-2 expression. Thus, HGF triggers activation of the COX-2 gene in gastric epithelial cells through phosphorylation of c-Met/ HGF receptor and activation of the ERK2 signaling pathway.-Jones, M. K., Sasaki, E., Halter, F., Pai, R., Nakamura, T., Arakawa, T., Kuroki, T., Tarnawski, A. S. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J. 13, 2186 -2194 (1999) 
tissue integrity, repair of gastrointestinal mucosal injury, and ulcer healing (1) (2) (3) . Such actions are particularly well documented for epidermal growth factor (EGF) (1) (2) (3) . It has been demonstrated that hepatocyte growth factor (HGF), a peptide with potent hepato-and renotrophic actions, also plays a role in gastric ulcer healing (4, 5) . HGF is secreted by cells of mesodermal origin and binds to the c-Met/HGF receptor on adjacent epithelial cells, thus mediating epithelial-mesenchymal interactions during the healing process (4) . In addition to the mitogenic, motogenic, and angiogenic properties, HGF also has unique morphogenic properties reflected by branching and gland lumen formation during the late remodeling phase of ulcer healing (4 -6) . Recent studies demonstrated that expression of HGF mRNA is significantly up-regulated at the margin of healing gastric ulcers (7, 8) .
The role of prostaglandins in the ulcer healing process is evidenced by the fact that nonsteroidal antiinflammatory drugs (NSAIDs), by inhibiting synthesis of prostaglandins, delay gastric ulcer healing and worsen the quality of mucosal scars (9, 10) . Similarly, the cell growth-promoting effect of prostaglandins has been demonstrated directly in human and in experimental animal models by a marked hyperplasia of the foveolar area of the gastric glands after prolonged treatment with prostaglandins (11, 12) , and indirectly by the inhibitory effect of some NSAIDs on development and growth of colonic polyps (13) . In some tissues, there is evidence for an interaction between prostaglandins and HGF expression. For example, it has been demonstrated that prostaglandins strongly induce HGF expression in skin fibroblasts (14) and, to a lesser extent, in gastric fibroblasts (15) . Conversely, HGF mRNA expression was found to be down-regulated at the edge of NSAID-induced gastric ulcers in humans (15) . Based on the latter observation, Takahashi et al. (15) postulated that prostaglandin deficiency causes decreased HGF induction and that this effect may represent the key mechanism of NSAIDs interference with ulcer healing. There is also evidence that HGF can induce prostaglandin synthesis through up-regulation of cyclooxygenase in human gastric carcinoma cells (16) and in rat hepatocytes (17) . These findings suggest an interaction between HGF and prostaglandin synthesis in mediating tissue growth and injury healing.
COX-2 gene expression has recently been demonstrated in rat gastric epithelial cells (18 -20) . We have demonstrated that expression and translation of this gene can be activated in the rat gastric epithelial cell line, RGM1, by epiregulin and basic fibroblast growth factor (19) . In vivo studies have revealed that expression of the EGF and HGF receptors is localized to undifferentiated epithelial cells at the margin of healing ulcers (2, 8) and that expression of the COX-2 enzyme is predominantly localized to adjacent nonepithelial cells (21) . This suggests the presence of a paracrine or possibly an autocrine regulatory pathway between these growth factors and prostaglandin synthesis.
The aims of this study were to determine whether HGF activates expression of COX-2 mRNA and protein in rat gastric epithelial cells and to investigate the possible signaling pathway(s) involved. We focused our attention on the role of the extracellular signal-regulated kinase (ERK) pathway, as we have recently demonstrated that MAP (ERK2) kinase is activated during healing of gastric ulcers and that interruption of this pathway with an inhibitor dramatically delays ulcer healing (22) . In addition, we examined the presence of the c-Met/HGF receptor in RGM1 cells and whether HGF induces phosphorylation of this receptor.
MATERIALS AND METHODS

Reagents
DMEM/F-12 and L-glutamine were purchased from Fisher Scientific (Springfield, N.J.). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, Ga.). PD98059 was purchased from Biomol Research Labs, Inc. (Plymouth Meeting, Pa.); SB203580 was purchased from Calbiochem (La Jolla, Calif.).
Cell culture
RGM1, an epithelial cell line derived from normal rat gastric mucosa (established by Hirofumi Matsui, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan), was obtained from Riken Cell Bank (Tsukuba, Japan) and used at passages 20 -28. The cells were maintained in DMEM/F12 medium containing 20% FBS and 2 mM of L-glutamine at 37°C with 5% CO 2 and 95% air in a humidified incubator. Cells were serum starved for 24 h prior to experiments. Cells were incubated in medium containing vehicle (controls) or the indicated concentrations of PD98059 (MAP kinase kinase [MEK] inhibitor) or SB203580 (p38 MAP kinase inhibitor) for 50 min. The cells were then treated for the time indicated with either vehicle (controls) or HGF (10 ng/ml). The dose of HGF was based on studies demonstrating that this dose significantly induces cell migration and cell proliferation in isolated epithelial cell lines, including RGM1 cells (4, 23) .
RT/PCR
Total RNA was isolated using the guanidium isothiocyanatephenol-chloroform method (24) . Reverse transcription and polymerase chain reaction (RT/PCR) were performed as described previously (25) (26) (27) . The PCR amplification was performed for 32 cycles of 1 min at 94°C for denaturing, 1 min at 55°C for annealing, and 2 min at 72°C for extension. The specific primer set used for rat COX-1 was 5Ј-AGC CCC TCA TTC ACC CAT TT-3Ј (forward) and 5Ј-CAC GGA CGC CTG TTC TAC GG-3Ј (reverse) (26) and for COX 2 was 5Ј-TGG TGC CGG GTC TGA TGA TG-3Ј (forward) and 5Ј-GCA ATG CGG TTC TGA TAC TG-3Ј (reverse) (28) .
Rat ␤-actin served as a positive control. The specific primer set used for rat ␤-actin (Clontech Laboratories Inc., Palo Alto, Calif.) was 5Ј-TTGTAACCAACTGGGACGATATGG-3Ј (forward) and 5Ј-CAGGCTGCAGTCCTTTGATC-3Ј (reverse) (29) . Nine microliter aliquots of the products were subjected to electrophoresis on a 1.25% agarose gel and DNA was visualized by ethidium bromide staining. Location of the products (base pairs, or bp) was determined by using a 100 bp ladder (Gibco BRL, Gaithersburg, Md.) as standard size marker.
Competitive RT/PCR
Since COX-1 mRNA, in contrast to COX-2 mRNA expression, remained unaffected with each of the various treatments, competitive RT/PCR was performed to quantify only COX-2 mRNA. Competitive RT/PCR was used to quantify the level of COX-2 mRNA by using one set of primers to amplify both the target cDNA and another DNA fragment, whereby the second DNA fragment competes with the target DNA for the same primers and thus acts as an internal standard (30, 31) . Serial dilutions of the competitor fragment were added to PCR amplification reactions containing constant amounts of the target cDNA samples. By knowing the amount of the competitor added to the reactions, the mRNA level can be quantitatively determined. The competitor DNA fragment was constructed using the MIMIC construction kit (Clontech Laboratories) according to the manufacturer's instructions. The primers used to construct the competitor fragment were 5Ј-TGG TGC CGG GTC TGA TGA TGC GCA AGT GAA ATC TCC TCC G-3Ј (forward) and 5Ј-GCA ATG CGG TTC TGA TAC TGT CTG TCA ATG CAG TTT GTA G-3Ј reverse). The underlined portions of the above primers are the target gene primer sequences; the remaining sequences were designed to yield a competitive PCR product approximately twice the size (450 bp) of the target cDNA PCR product (253 bp). PCR amplification was performed with the indicated concentrations of competitor fragment for 36 cycles of 1 min at 94°C for denaturing, 1 min at 55°C for annealing, and 2 min at 72°C for extension. For quantitative assessment of the PCR products, we used a video image analysis (Image-1/FL, Universal Imaging Corp., Westchester, Pa.) (32) . The Image-1 system can distinguish density on a scale of 0 -255 units. Each measurement was standardized by subtracting the background intensity in average.
Western blotting
To determine the effect of HGF on COX-2 protein synthesis, cells were treated for 5 min with either HGF (10 ng/ml) or vehicle (controls). Then the cells were washed and incubated in fresh serum-free medium for an additional 3 and 6 h. To determine the effect of MAP (ERK1, 2) kinase inhibition on COX-2 protein synthesis, cells were incubated for 50 min with either vehicle (controls) or the indicated concentrations of PD 98059 or SB203580. Cells were then treated for 5 min with either HGF (10 ng/ml) or vehicle (controls), washed, and incubated in fresh serum-free medium for an additional 3 h and lysed. Protein content of each lysate was determined as described (33) . Western blotting was performed as described previously (25) . Membranes were incubated with a specific polyclonal antibody against rat COX-2 (Cayman Chemical Co., Ann Arbor, Mich.) diluted 1:1000 for 1 h. The bound antigen-antibody complexes were detected with anti-rabbit immunoglobulin G-horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.), using enhanced chemiluminescence (Amersham, Arlington Heights, Ill.), and exposed to Amersham ECL detection film. Quantification of COX-2 protein signals was performed by laser densitometry (Pharmacia LBK Biotechnology, Uppsala, Sweden).
Determination of mitogen-activated protein kinase activity
ERK2 activity was determined as described previously (22) . Briefly, cells were incubated in medium containing either vehicle (controls) or the indicated concentration of PD98059 or SB203580 for 50 min, followed by treatment with either HGF (10 ng/ml) or vehicle (controls). The cells were then lysed on ice; 30 g of total protein from each experimental sample was added to a conjugate of protein A Sepharose and 1 g anti-ERK2 antibody (Santa Cruz Biotechnology) and mixed at 4°C for 2 h. The conjugates were then pelleted by centrifugation and washed four times. After the final wash, buffer was removed completely and 40 l of MAPK assay mixture (10 mM HEPES, pH 7.5; 10 mM MgCl 2 ; 50 M ATP; 30 g myelin basic protein; and 4 Ci [ 32 P] ATP) was added to each sample. The samples were incubated at 30°C for 20 min and the reaction was terminated by the addition of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer (34) . The samples were then electrophoresed on 15% acrylamide gels. After electrophoresis, the gels were stained with Coomassie brilliant blue and dried. The gels were autoradiographed; the myelin basic protein bands were cut out and radioactivity was counted in a scintillation counter.
Determination of c-Met/HGF receptor phosphorylation levels
Phosphorylation levels of the c-Met/HGF receptor were determined as described for the EGF receptor (22) . Briefly, cells were incubated in medium containing either vehicle (controls) or PD98059 (20 M) for 50 min, followed by incubation with either HGF (10 ng/ml) or vehicle (controls) for 5 min. The cells were then lysed and the c-Met/HGF receptor was immunoprecipitated from 0.4 mg of total cell protein for each condition by addition of 1 g anti-c-Met/HGF antibody (Santa Cruz Biotechnology) conjugated with protein A-Sepharose. After immunoprecipitation, the immunoprecipitates were electrophoresed on 7.5% polyacrylamide gels and transferred to nitrocellulose membranes for immunoblot
immunoprecipitated under each condition. Phosphorylation levels were determined by quantification of intensity measurements using the Image-1 video image analysis system with normalization for amounts of protein immunoprecipitated.
Statistical analysis
Student's t test was used to compare data between two groups (e.g., control and growth factor-treated group). One-way ANOVA and Bonferroni correction were used to compare data between three or more groups. Values are expressed as mean Ϯ standard deviation (sd). P values less than 0.05 were considered significant.
RESULTS
Cell viability
Cell viability was determined by the fast green exclusion method as described previously (35) . After 50 min treatment with MEK (mitogen-activated protein kinase/ERK kinase) inhibitor (20 M), RGM1 cells had a viability of 93.8 Ϯ 6%. There was no statistical difference in viability compared to that of control cells.
COX-1 and COX-2 mRNA expression in RGM1 cells
RT/PCR was performed to determine whether RGM1 cells at baseline express mRNA for COX-1 and COX-2. As shown in Fig. 1 and Fig. 2 , mRNAs for both isoenzymes were present in RGM1 cells at baseline. One hour incubation with 10 ng/ml HGF did not affect COX-1 mRNA expression (Fig. 1 ), but caused a marked increase in COX-2 mRNA expression (Fig. 2) . COX-2 mRNA expression returned to baseline by 6 h (Fig. 2) .
Competitive RT/PCR was used to quantify PCR products for COX-2 (Fig. 3A) . The initial amount of COX-2 cDNA can be determined as equal to that of MIMIC, when both products after PCR are in equal amount. Accordingly, using 1 ϫ 10 Ϫ2 attomol/ml of MIMIC, expression of COX-2 mRNA was compared (Fig. 3B, C) . One hour incubation with 10 ng/ml HGF led to a significant increase in COX-2 mRNA expression by 236 Ϯ 56% (PϽ0.01 vs. control). Pretreatment with the MEK inhibitor PD98059 (20 M) completely inhibited the HGF-induced increase in COX-2 mRNA expression. However, PD98059 did not affect COX-2 mRNA expression when added alone (Fig. 3B, C) .
Effect of HGF on COX-2 protein expression
Western blotting was performed to determine whether COX-2 protein expression is affected by treatment with HGF. HGF at the concentration 10 ng/ml significantly increased COX-2 protein levels after 3 h (159Ϯ19% vs. controls, PϽ0.003). As shown in Fig. 4 , HGF at this concentration resulted in a 175 Ϯ 24% increase vs. controls (PϽ0.02) at 6 h. Pretreatment with 20 M of PD98059 for 50 min completely prevented the HGF-induced increase in COX-2 protein level. PD98059 did not affect COX-2 protein level at the baseline (Fig. 4) . Pretreatment for 50 min with SB203580 (a specific inhibitor of the MAP kinase, p38), at concentrations of 10 M to 40 M, had no effect on the HGF-induced increase in COX-2 protein levels (Fig. 5) .
Effect of HGF on ERK2 activity
Five minute and 1 h incubations with 10 ng/ml HGF significantly increased ERK2 activity by 684 Ϯ 27% and 153 Ϯ 6%, respectively (both PϽ0.01 vs. control). Pretreatment with 20 M PD98059 completely blocked the HGF-induced increase in ERK2 activity (Fig. 6) . Maximal inhibition of the HGF-induced increase in ERK2 activity was obtained by pretreatment with PD98059 at a concentration of between 10 M and 25 M (Fig. 7A) . The concentration of 20 M PD98059 used throughout the present study was chosen because it gave maximal inhibition without affecting cell viability (see above). Pretreatment with SB203580 at concentrations of 1 M to 40 M had no effect on the HGF-induced increase in ERK2 activity (Fig. 7B) .
Effect of HGF on c-Met/HGF receptor expression and phosphorylation
Five minute incubation of RGM1 cells with 10 ng/ml HGF triggered more than a 13-fold increase in c-Met/HGF receptor phosphorylation (PϽ0.005, Fig. 8 ). Pretreatment with 20 M PD98059 for 50 min, which abolished the HGF-induced increase in ERK2 activity, had no effect on c-Met/HGF receptor phosphorylation (Fig. 8) .
DISCUSSION
The two isoforms of the prostaglandin-synthesizing enzyme cyclooxygenase (COX-1 and COX-2), appear to have different biological roles (36 -38) . COX-1 is expressed constitutively in most tissues, and prostaglandins produced in normal gastric tissue have been claimed to be derived predominantly from COX-1 (36) . The COX-1 isoform is abundantly expressed in gastric mucosa and is considered to exert, through generation of prostaglandins, a 'housekeeping' function essential for gastric protection. In contrast, the COX-2 isoform is inducible and found predominantly in inflammatory exudates in rheumatic disease (36 -38) . Its activation occurs in certain cell types in response to proinflammatory or mitogenic agents including cytokines, endotoxins, and tumor promoters (39) . Expression of COX-2 mRNA in RGM cells after 1 h, 3 h, and 6 h incubations with HGF (10 ng/ml). One hour incubation with HGF led to a significant increase in COX-2 mRNA expression compared to vehicle-treated controls (ct), which returned to baseline by 6 h. The quantitative assessments of the PCR products were performed using a video analysis system. Values are the mean intensity Ϯ sd of three independent experiments. n.s., not significant.
This study demonstrates that COX-2 mRNA, in addition to COX-1 mRNA, is expressed in the gastric epithelial cell line RGM1, which is derived from normal rat gastric mucosa. Furthermore, it clearly demonstrates that HGF does not affect the constitutively expressed COX-1 gene but significantly increases the expression of COX-2 mRNA and protein in gastric epithelial cells. Moreover, our study shows for the first time that COX-2 gene activation in gastric epithelial cells is mediated through the MAP (ERK2) kinase signaling pathway. Although the an- Incubation with HGF (10 ng/ml) for 6 h significantly increased COX-2 protein levels. Incubation with HGF (10 ng/ml) for 3 h also significantly increased COX-2 protein levels (see text). Pretreatment for 50 min with PD98059 completely abolished the HGF-induced increase in COX-2 protein level, but did not affect COX-2 protein level at the baseline (not treated with HGF). The COX-2 protein bands were quantified by laser densitometry. Values are the mean density Ϯ sd of three independent experiments. **P Ͻ 0.05. tibody used in the present study for the determination of ERK2 activity is known to cross react with ERK1, we were unable to demonstrate growth factorinduced ERK1 activity in RGM1 cells when using an anti-ERK1 antibody (data not shown). Therefore, although we cannot completely rule out the possible involvement of ERK1 in the HGF-induced expression of COX-2, our data suggest that ERK2 is the predominant mediator of this induction. We have also demonstrated that gastric epithelial cells express the c-Met/HGF receptor and that a dramatic activation of c-Met/HGF receptor and ERK2 activity occurs within 5 min after stimulation by HGF and lasts for at least 1 h. The latter findings represent the first demonstration of c-Met/HGF receptor expression in RGM1 cells and ERK2 activation in gastric epithelial cells by HGF. Activation of the MAP (ERK) kinase pathway is responsible for the mitogenic and motogenic properties of growth factors in other tissues (40) and also plays an important role in gastric ulcer healing (22) . Recently it was shown that COX-2 expression induced by interleukin-1 in human fibroblasts and by bacterial lipopolysaccharide in human monocytes involves p38 MAP kinase (41, 42) . We used a specific inhibitor of p38 MAP kinase in the present study to investigate the possibility that this kinase, in addition to ERK, is involved in the HGFinduced expression of COX-2. Inhibition of p38 MAP kinase did not affect induction of the COX-2 gene by HGF, clearly indicating that HGF-induced expression of COX-2 in gastric epithelial cells is mediated through the ERK signaling pathway and is independent of p38 MAP kinase.
The presence of COX-2 in the gastric mucosa in vivo is indicated by recent observations made from immunohistochemical studies (21, (43) (44) (45) (46) (47) (48) and by studies demonstrating expression of COX-2 mRNA in gastric mucosal tissue (45-47, 49 -53) . In general, induction of COX-2 has been regarded as a mechanism by which cells increase the capacity to synthesize prostaglandins in excess of that provided by COX-1 (54, 55) . Recent studies of COX-1-and-COX-2-deficient mice suggest that COX-1 and COX-2 use different subcellular pools of arachidonic acid for synthesis of prostaglandins (56, 57) . Large amounts of both COX-2 and cytosolic phospholipase A 2 have been found to be localized to the nuclear envelope whereas COX-1 is also found in the endoplasmic reticulum (58) . Thus, MAPK-mediated activation of cytosolic phospholipase A 2 in the nuclear envelope may lead to a preferential generation of prostaglandins by COX-2.
The importance of COX-2 in ulcer healing is well established (21, 52, 53) . First, COX-2-selective inhibitors delay ulcer healing; second, there is a close correlation between the amount of COX-2 (assessed by immunoreactivity) present and the epithelial cell proliferation rate at the ulcer margin (21) . The role of COX-2 in mucosal protection is also emerging from recent studies. Animal experiments and limited clinical studies have shown that highly selective COX-2 inhibitors do not damage the unchallenged gastric mucosa (21, 59 -61) . They abolish, however, peptone-induced gastric mucosal protection against ethanol injury and abolish mucosal protection induced by mild irritants, e.g., 20% ethanol (62, 63) . Moreover, acute ischemia-reperfusion induces (a significant) up-regulation of COX-2 mRNA in the rat gastric mucosa to the same level as COX-1 mRNA, before induction of gastric ulceration (51) . The latter observations suggest that COX-2 can, 'on demand', assist the housekeeping effect of COX-1 as a second line of defense.
In summary, our present study has demonstrated that RGM1 (a cell line derived from normal rat gastric epithelium) cells express both COX-1 and COX-2, and that HGF triggers activation of COX-2 mRNA and protein in these cells. Furthermore, our study has demonstrated that RGM1 cells express the c-Met/HGF receptor protein and that HGF-triggered activation of COX-2 expression in these cells is mediated through phosphorylation of the c-Met/ HGF receptor and activation of the MAP (ERK2) kinase signal transduction pathway. Since COX-2 is important to ulcer healing, the above actions of HGF provide a molecular basis for its participation in the ulcer healing process. 
